The PHOENIX group recorded solid results in the first six months of fiscal year 2023/24 (31 July 2023), despite a persistently challenging market environment.

The company has set an official target to become CO₂ -neutral in its own business operations by the year 2030. We want to avoid and reduce our emissions by at least 30 per cent (Scope 1 + 2 emissions). PHOENIX thereby underlines its commitment to creating added value for society and the environment beyond our mission in the healthcare sector.

The PHOENIX group has completed the acquisition of parts of McKesson Europe, following the clearance by competition authorities of the full scope of the transaction. The closing took place on 31 October 2022. 

The PHOENIX group supports aid organisations in Ukraine quickly and unbureaucratically with urgently needed pharmaceutical products. Through its national subsidiaries in Bulgaria, Hungary, Romania, Slovakia, and the Baltic States, the healthcare provider is currently preparing the delivery of medicines, bandages and medical equipment. In addition, the PHOENIX group is putting together another shipment from Germany in close coordination with the German pharmaceutical wholesale association “PHAGRO - Bundesverband des pharmazeutischen Großhandels”.

For fiscal year 2022/23 (31 January 2023), the PHOENIX group has once again presented solid key financial figures in a challenging environment. Strengthened by the completion of the acquisition of parts of McKesson Europe, the healthcare provider has further expanded its leading position in Europe.

The intelligent and cloud-based medication system Smila helps to improve healthcare for patients.